Skip to main content
Top
Published in: Journal of Gastroenterology 6/2011

01-06-2011 | Original Article—Liver, Pancreas, and Biliary Tract

Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids

Authors: Kensuke Kubota, Seitaro Watanabe, Takashi Uchiyama, Shingo Kato, Yusuke Sekino, Kaori Suzuki, Hironori Mawatari, Hiroshi Iida, Hiroki Endo, Koji Fujita, Masato Yoneda, Hirokazu Takahashi, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Kazuya Sugimori, Kantaro Hisatomi, Nobuyuki Matsuhashi, Hirotaka Sato, Emiko Tanida, Takashi Sakaguchi, Nobutaka Fujisawa, Atsushi Nakajima

Published in: Journal of Gastroenterology | Issue 6/2011

Login to get access

Abstract

Background

Relapse and spontaneous remission (SR) are characteristic features of autoimmune pancreatitis (AIP).

Aim and methods

We conducted a study to determine if the predictive factors might be potentially related to the relapse in 70 consecutive AIP patients. Regarding SR, we studied the data of patients without corticosteroid treatment (CST).

Results

CST was administered to 60% (42/70) of the patients; however, relapse was noted in 45.2% (19/42) of these patients. In 95% (18/19) of the AIP patients developing relapse, the relapse occurred within 3 years. The relapse rate was 80% (12/15) in the AIP patients administered CST for less than 12 months and 25.9% (7/27) in those administered CST for over 12 months (p < 0.01). The results of univariate analysis revealed significant association of relapse with the presence of jaundice, IgG4 seropositivity, presence of diffuse pancreas swelling, duodenal papillitis (DP), history of initial CST, and history of supportive treatment (p < 0.05), whereas multivariate analysis revealed that IgG4 seropositivity (OR 10.506, p = 0.0422) and the presence of jaundice (OR 6.945, p = 0.0174) are significant independent factors predictive of relapse in AIP patients. SR was recognized in 65.0% (13/20) of AIP patients without CST. The results of univariate analysis revealed that SR was associated with IgG4 seropositivity (p < 0.05), and multivariate analysis identified IgG4 seropositivity (OR 0.032, p = 0.0092) as a significant independent factor predictive of SR in these cases.

Conclusion

AIP patients with IgG4 seropositivity and jaundice are at a higher risk of relapse and they could therefore be candidates for over 3 years of maintenance CST. AIP patients with IgG4 seronegativity have a high likelihood of SR.
Literature
1.
go back to reference Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas: an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.PubMedCrossRef Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas: an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.PubMedCrossRef
2.
go back to reference Yoshida K, Toki F, Takeuti T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.PubMedCrossRef Yoshida K, Toki F, Takeuti T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.PubMedCrossRef
3.
go back to reference Hamano H, Kawa S, Horiuchi A, Unnno H, Furuta N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.PubMedCrossRef Hamano H, Kawa S, Horiuchi A, Unnno H, Furuta N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.PubMedCrossRef
4.
go back to reference Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999;354:43–4.PubMedCrossRef Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999;354:43–4.PubMedCrossRef
5.
go back to reference Kubota K, Iida H, Fujisawa T, Yoneda M, Inamori M, Kirikoshi H, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–51.PubMedCrossRef Kubota K, Iida H, Fujisawa T, Yoneda M, Inamori M, Kirikoshi H, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–51.PubMedCrossRef
6.
go back to reference Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis. Strategy for steroid treatment. Pancreas. 2005;30:31–9.PubMed Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis. Strategy for steroid treatment. Pancreas. 2005;30:31–9.PubMed
7.
go back to reference Takayama M, Hamano H, Ochi Y, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99:932–7.PubMedCrossRef Takayama M, Hamano H, Ochi Y, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99:932–7.PubMedCrossRef
8.
go back to reference Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2006;56:1719–24.CrossRef Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2006;56:1719–24.CrossRef
9.
go back to reference Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139:140–8.PubMedCrossRef Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139:140–8.PubMedCrossRef
10.
go back to reference Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levt MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.PubMedCrossRef Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levt MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.PubMedCrossRef
11.
go back to reference Kubota K, Iida H, Fujisawa T, Ogawa M, Inamori M, Saito S, Kakuta Y, Oshiro H, Nakajima A. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas. 2007;35:e51–60.PubMedCrossRef Kubota K, Iida H, Fujisawa T, Ogawa M, Inamori M, Saito S, Kakuta Y, Oshiro H, Nakajima A. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas. 2007;35:e51–60.PubMedCrossRef
12.
go back to reference Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa S, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan–Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008;43:403–8.PubMedCrossRef Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa S, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan–Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008;43:403–8.PubMedCrossRef
13.
go back to reference Bodily KD, Takahashi N, Fletcher JG, Finder J, Hough DM, Kawashima A, Chari ST. Autoimmune pancreatitis: pancreatic and extrapancreatic imaging findings. AJR. 2009;192:431–7.PubMedCrossRef Bodily KD, Takahashi N, Fletcher JG, Finder J, Hough DM, Kawashima A, Chari ST. Autoimmune pancreatitis: pancreatic and extrapancreatic imaging findings. AJR. 2009;192:431–7.PubMedCrossRef
14.
go back to reference Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid therapy for autoimmune pancreatitis. GUT. 2009;58:1504–7.PubMedCrossRef Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid therapy for autoimmune pancreatitis. GUT. 2009;58:1504–7.PubMedCrossRef
15.
go back to reference Ghazale A, Chari S. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56:1650–2.PubMedCrossRef Ghazale A, Chari S. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56:1650–2.PubMedCrossRef
16.
17.
go back to reference Nakazawa T, Ohara H, Sano H, Ando T, Joh T. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32:229.PubMedCrossRef Nakazawa T, Ohara H, Sano H, Ando T, Joh T. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32:229.PubMedCrossRef
18.
go back to reference Ito T, Nishimori I, Inoue N, Kawabe K, Gibo J, Arita Y, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;24(Suppl 18):50–8.CrossRef Ito T, Nishimori I, Inoue N, Kawabe K, Gibo J, Arita Y, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;24(Suppl 18):50–8.CrossRef
19.
go back to reference Unno H, Saegusa H, Fukushima M, Hamano H. Usefulness of endoscopic observation of the main duodenal papilla in the diagnosis of sclerosing pancreatitis. Gastrointest Endosc. 2002;56:880–4.PubMedCrossRef Unno H, Saegusa H, Fukushima M, Hamano H. Usefulness of endoscopic observation of the main duodenal papilla in the diagnosis of sclerosing pancreatitis. Gastrointest Endosc. 2002;56:880–4.PubMedCrossRef
20.
go back to reference Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuti K, Kamisawa T, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32:244–8.PubMedCrossRef Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuti K, Kamisawa T, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32:244–8.PubMedCrossRef
21.
go back to reference Ito T, Kawabe K, Arita Y, Hisano T, Igarashi H, Funakoshi A, et al. Evaluation of pancreatic endocrine function in patients with autoimmune pancreatitis. Pancreas. 2006;34:254–9.CrossRef Ito T, Kawabe K, Arita Y, Hisano T, Igarashi H, Funakoshi A, et al. Evaluation of pancreatic endocrine function in patients with autoimmune pancreatitis. Pancreas. 2006;34:254–9.CrossRef
22.
go back to reference Uchida K, Yazumi S, Nishio A, Kusuda T, Koyabu M, Furuta M, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.PubMedCrossRef Uchida K, Yazumi S, Nishio A, Kusuda T, Koyabu M, Furuta M, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.PubMedCrossRef
23.
go back to reference Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.CrossRef Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.CrossRef
24.
go back to reference Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M, working members of research committee for intractable pancreatic disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471–7.PubMedCrossRef Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M, working members of research committee for intractable pancreatic disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471–7.PubMedCrossRef
25.
go back to reference Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134:440–6.CrossRef Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134:440–6.CrossRef
Metadata
Title
Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids
Authors
Kensuke Kubota
Seitaro Watanabe
Takashi Uchiyama
Shingo Kato
Yusuke Sekino
Kaori Suzuki
Hironori Mawatari
Hiroshi Iida
Hiroki Endo
Koji Fujita
Masato Yoneda
Hirokazu Takahashi
Hiroyuki Kirikoshi
Noritoshi Kobayashi
Satoru Saito
Kazuya Sugimori
Kantaro Hisatomi
Nobuyuki Matsuhashi
Hirotaka Sato
Emiko Tanida
Takashi Sakaguchi
Nobutaka Fujisawa
Atsushi Nakajima
Publication date
01-06-2011
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 6/2011
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0393-y

Other articles of this Issue 6/2011

Journal of Gastroenterology 6/2011 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Pomalidomide suppresses cerulein-induced acute pancreatitis in mice

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine